ArticleFrontiers in oncology2025
Value of contrast-enhanced ultrasound assisted core needle biopsy in the diagnosis of cervical lymph node tuberculosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ultrasound-Guided Needle Aspiration Biopsy for Superficial Cervical Lymphadenopathy: Diagnostic Yield Beyond Tuberculosis.Diagnostics (Basel, Switzerland) · 2026Article
- Necrotizing (Abscessing) Lymphadenopathy and the Diagnostic Value of Contrast-Enhanced Ultrasound (CEUS): A Review with Clinical Vignettes.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical Value of Contrast-Enhanced Ultrasound and Ultrasound Elastography in the Pathological Classification and Treatment Response Prediction of Cervical Tuberculous Lymphadenitis.Infection and drug resistance · 2026Article
- Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the value of contrast-enhanced ultrasound (CEUS) assisted core needle biopsy (CNB) in the diagnosis of cervical lymph node tuberculosis (LN TB) and improve the positive rate of cervical LN TB. Methods: We retrospectively analyzed 730 samples obtained from July 2010 to January 2025 from patients treated with effective antituberculosis therapy and with microbiologically confirmed and surgical pathologically proven cervical lymph node enlargement who had undergone CEUS- CNB at our hospital. All patients were divided into two groups according to the historical control method. The CEUS group (2017-2025) underwent CEUS- CNB (485 cases), whereas the US group (2010-2018) underwent US-guided CNB (245 cases). The positive rates of pathological diagnosis and Xpert Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (MTB/RIF) assay diagnoses were compared between the groups. Results: The specimens' integrity was significantly higher after CNB in the CEUS group than in the US group (CEUS group: 72.30%; US group: 45.49%), and visual satisfaction of sampling in the CEUS group was higher (χ2: 47.651, P < 0.001). Histopathological examination sensitivity, specificity, positive predictive value, and negative predictive value were higher in the CEUS group than in the US group. The sensitivity of the Xpert MTB/RIF assay was significantly higher in the CEUS group than in the US group. Conclusion: The study results support the clinical use of CEUS for improving the diagnostic performance and positive rate for cervical LN TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.